Inventor of Axiostat Hemostatic Agent
Leo Mavely is the inventor of Axiostat, a chitosan-based hemostatic dressing developed by Axio Biosolutions.
Background on Axiostat
- Axiostat is a chitosan-based hemostatic dressing that has demonstrated effectiveness in controlling venous and moderate arterial bleeding, particularly in situations where access to the bleeding site is difficult 1
- The product serves as an adjunct to traditional surgical techniques for hemorrhage control, as supported by clinical guidelines 1
- Axiostat was developed by Axio Biosolutions, with Leo Mavely as the founder and inventor of the technology
Clinical Applications of Axiostat
- Axiostat is primarily recommended for venous or moderate arterial bleeding associated with parenchymal injuries 1
- The hemostatic dressing has shown significant efficacy in pre-hospital settings, reducing hemostasis time to 4.68 ± 1.04 minutes compared to 18.56 ± 5.04 minutes with conventional cotton gauze 2
- Successful hemostasis was achieved in 94% of patients using Axiostat compared to 74% with cotton gauze in trauma settings 2
Mechanism of Action
- Like other chitosan-based hemostatic agents, Axiostat works by interacting with blood components to accelerate clotting 1
- The chitosan in Axiostat is a naturally occurring cationic biopolymeric material derived from chitin, which has demonstrated biological properties including acceleration of wound healing, hemostasis, and antimicrobial action 3
- The product is particularly valuable when access to the site of bleeding is challenging 1
Comparative Effectiveness
- In dental extractions for patients on antiplatelet therapy, Axiostat achieved hemostasis in 1.25 ± 0.06 minutes compared to 1.89 ± 0.54 minutes with platelet-rich fibrin 3
- In femoral arterial access site closure, Axiostat demonstrated 91.7% primary technical success in achieving hemostasis when used to aid manual compression 4
- However, caution is warranted in some applications - a study of radial artery hemostasis following coronary angioplasty showed an unexpectedly high incidence of radial thrombosis (19.5%) despite 78% success rate in achieving hemostasis 5
Important Considerations
- The use of topical hemostatic agents like Axiostat should consider factors such as the type of surgical procedure, cost, severity of bleeding, and the patient's coagulation status 1
- European guidelines recommend using topical hemostatic agents like Axiostat in combination with other surgical measures or with packing for optimal results 1
- Axiostat allows for easier removal from the wound site without leaving residue, which helps in rendering the wound clean for further treatment 2